In vitro induction of cartilage-specific macromolecules by a bone extract.

An in vitro system has been developed to study the onset of chondrogenesis. Embryonic rat muscle mesenchymal cells, when treated in suspension culture with an extract of bovine bone matrix, synthesized cartilage-specific proteoglycan and type II collagen. The synthesis of these two macromolecules was assayed by the enzyme-linked immunosorbent assay inhibition technique. Further evidence of chondrogenesis was demonstrated by morphological changes of treated cells when cultured in firm agarose and stained for metachromatic matrix. Even with crude bone matrix extracts, the assay was sensitive at the microgram level and significant differences in cartilage macromolecules compared with controls were observed in 2-3 d. In vivo the same extract induced first cartilage and then bone.

Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures.

TGF-beta 1 is a polypeptide that is abundant in bone matrix, is produced by bone cells, and modulates proliferation and differentiated functions of osteoblastic cells in vitro. TGF-beta 2 is a closely related polypeptide that was originally isolated from bone matrix. TGF-beta 1 has been shown previously to stimulate prostaglandin production in cultures of neonatal mouse calvariae, which causes these bones to resorb. We found similar effects with TGF-beta 2. In comparison, TGF-beta 1 and TGF-beta 2 failed to stimulate bone resorption in fetal rat long bone cultures during a 3-d incubation period in concentrations up to 50-100 times greater than those capable of inducing bone resorption in calvariae. Incubation with TGF-beta 1 for a further 3 d decreased bone resorption up to 30%. Moreover, bone resorption induced by the bone-resorbing agents IL 1 and 1,25-dihydroxyvitamin D3 was partially or completely inhibited by TGF-beta 1 and TGF-beta 2 during the second half of the 6-d incubation period. Inhibition of DNA synthesis with hydroxyurea inhibited bone resorption in long bones in a similar pattern to that seen with TGF-beta 1. The inhibitory effects of TGF-beta 1 and TGF-beta 2 on bone resorption in long bone cultures may therefore be due to inhibition of osteoclast precursor proliferation.

Binding of transforming growth factor-beta to cell surface proteins varies with cell type.

Transforming growth factor-beta (TGF beta 1 and TGF beta 2) bind to several different cell surface proteins, including a high Mr proteoglycan. We found that on primary and early passage cultures of fibroblasts, chondroblasts, and osteoblasts TGF beta 1 binds to both the high Mr proteoglycan and to lower Mr components, whereas on epithelial, endothelial, and lymphoid-derived cells TGF beta 1 only binds to the lower Mr species. With cell lines, this distinction is lost. Further analysis indicated that binding to the high Mr proteoglycan is not necessary for TGF beta 1 induced regulation of DNA, collagen and fibronectin synthesis, change in cell morphology, or reorganization of the actin cytoskeleton. We propose that the lower Mr components are the active receptors mediating these events.

Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.

Several studies in recent years have shown that the pyridinium crosslinks of collagen provide good urinary markers of collagen degradation, primarily reflecting bone resorption. Most studies, however, were based on time-consuming HPLC assays of the crosslinks. We now describe the development of an immunoassay (ELISA) based on a monoclonal antibody for free deoxypyridinoline (Dpd) and its use in healthy individuals and patients with bone-related disorders to measure the urinary excretion of Dpd as an improved assessment of bone resorption rate. The Dpd antibody exhibited less than 1% cross-reaction with free pyridinoline and was shown to react only with free Dpd in urine, having no significant interaction with peptide forms of the crosslinks. The intra- and interassay variations were less than 10 and 15%, respectively. A total of 402 urine samples from patients and healthy volunteers were analyzed by both the immunoassay and HPLC. The ELISA results were highly correlated with those for total Dpd measured by HPLC over the full range of sample groups (r = 0.95). In normal adults, the excretion of Dpd (mean +/- SD) was 4.7 +/- 1.6 nmol/mmol creatinine, with about fivefold higher excretion rates in children. For 31 osteoporotic patients, the ELISA Dpd values (median 6.7; range 3.0-13.5 nmol/mmol Cr) were significantly higher (p < 0.0001) than the corresponding values for age- and sex-matched controls (median 4.0; range 1.8-7.4). The difference between the groups was similar for total Dpd by HPLC (osteoporotic: mean 12.8, range 4.8-30.7; controls: 6.6, range 3.0-18.1; p < 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)

Immunoassay for urinary pyridinoline: the new marker of bone resorption.

Urinary pyridinoline (Pyd) and deoxypyridinoline (Dpd) are markers of bone resorption that are elevated above normal in subjects with metabolic bone disease. Total Pyd and Dpd, both free and peptide-bound forms, can be measured by HPLC after hydrolysis and cellulose chromatography. Since free Pyd is the major component of total Pyd in urine, we developed an immunoassay using free Pyd as an immunogen. This assay is much easier to perform than HPLC, requires no sample preparation, and correlates well with total Pyd measurement by HPLC (r = 0.97) and with urinary hydroxyproline (r = 0.90). The antiserum reacts most strongly with free Pyd and Dpd and minimally with glycosylated and large peptide-bound forms. The sensitivity of the Pyd immunoassay is less than 25 nM. The intraassay CV is 5-10%; the interassay CV is 10-15%. Analytic recovery studies indicated negligible sample interference. Furthermore, measurement of the Pyd in the same individuals over a 30 day time period exhibited minimal day-to-day variation. Thus, the Pyd immunoassay provides a rapid and easy method for evaluation of Pyd in urine. Pyd immunoassay may serve as a practical method of screening for metabolic bone disease and for monitoring therapeutic treatment.

Inhibitory effects of the bone-derived growth factors osteoinductive factor and transforming growth factor-beta on isolated osteoclasts.

Demineralized bone matrix contains a number of growth factors for osteoblast-like cells. Two of these, the novel glycoprotein osteoinductive factor (OIF) and transforming growth factor-beta (TGF beta), act together to cause ectopic bone formation in vivo. Since OIF, like TGF beta, is likely released from bone when the matrix is resorbed, we examined the effects of homogeneous OIF and TGF beta on osteoclast function. Osteoclast function was tested in isolated avian osteoclasts and was measured in terms of tartrate-resistant acid phosphatase (TRAP) activity, oxygen-derived free radical production, and formation of characteristic resorption lacunae on slices of sperm whale dentine. OIF (50-100 ng/ml) inhibited the capacity of these osteoclasts to form lacunae whether assessed by the number of excavations per slice or by the total area resorbed. OIF (10-100 ng/ml) or TGF beta (10-20 ng/ml) caused a decrease in TRAP activity as well as a reduction in oxygen-derived free radical generation detected by nitroblue tetrazolium staining. TGF beta had no effect on the resorption capacity of isolated osteoclasts in concentrations that inhibited TRAP activity and nitroblue tetrazolium staining. These results suggest that growth regulatory factors, such as OIF and TGF beta, released during the resorption of bone may be endogenous inhibitors of continued osteoclastic activity. This cessation of osteoclast activity may be an essential preliminary step to the new bone formation that occurs at resorption sites during bone remodeling.

Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans.

Bisphosphonates have been shown to decrease bone turnover in a variety of high turnover states. We postulated that pamidronate (APD), a bisphosphonate, could prevent the increased bone turnover caused by thyroid hormone excess. Twenty-two male subjects were randomized to receive either placebo (group 1) or APD (30 mg, iv, daily for 2 days; group 2). Subsequently, all subjects received T3 (50 micrograms, twice daily, for 8 days). Biochemical indices of bone turnover were measured in blood and urine at baseline, after treatment with APD/placebo, and after treatment with T3. The urinary calcium/creatinine ratio (Uca/cr) fell significantly after treatment with APD, but not after treatment with placebo (group 1, 0.131 +/- 0.021; group 2, 0.040 +/- 0.013 mmol Ca/mmol Cr; P < 0.002). After treatment with T3, Uca/cr rose significantly in group 1, but not in group 2 (group 1, 0.275 +/- 0.042; group 2, 0.065 +/- 0.025 mmol Ca/mmol Cr; P < 0.05). Thus, APD prevented the rise in Uca/cr caused by treatment with T3. Similar results were obtained with urinary hydroxyproline and urinary pyridinoline cross-links. We conclude that 8 days of mild thyroid hormone excess in normal men increases bone turnover, and prior administration of APD prevents thyroid hormone-induced increases in bone resorption. APD may be useful in the prevention of thyroid hormone-induced osteopenia.

Osteogenesis in rats with an inductive bovine composite.

Subcutaneous (S.C.) implantation of allogeneic demineralized bone matrix in rats results in endochondral bone formation. In contrast, implants of bovine demineralized bone matrix in rat S.C. tissue show inconsistent cartilage and bone formation, presumably due to an intense inflammatory reaction at the implant site. To overcome this response, a partially purified bone inducing extract was prepared from bovine bone by a series of steps that included demineralization, guanidine/HCl extraction, gel filtration, and cation exchange chromatography. To develop a carrier, the inactive guanidine/HCl-extracted matrix was then trypsinized to remove the inflammatory and immunogenic components, thus yielding a predominantly collagenous matrix. Bovine composites were prepared by combining different amounts of the bone inducing extract with a carrier that consisted of the trypsinized bone matrix and purified soluble bovine dermal collagen. Subcutaneous implantation of the composite preparation resulted in dose-dependent endochondral bone formation in rats. The inductive activity and the low-level inflammatory response were comparable to allogeneic implants.

Osteoinduction: a report on the discovery and research of unique protein growth factors mediating bone development.

Osteoinductive factor, a unique glycoprotein, is the latest growth factor to be discovered. When combined with transforming growth factor-beta 1 or transforming growth factor-beta 2, osteoinductive factor can stimulate the formation of endochondral bone in a collagen-ceramic composite. Preliminary laboratory studies indicate a wide potential for the use of osteoinductive products in orthopedics, oral reconstruction, and periodontal procedures.

The high molecular weight receptor to transforming growth factor-beta contains glycosaminoglycan chains.

Proteoglycans are constituents of the cell surface that may play important roles in the regulation of cell behavior. Here we report that the 250-kDa receptor subunit that binds the multifunctional protein, transforming growth factor-beta 1 (TGF-beta 1), contains chains of heparan sulfate and chondroitin sulfate and thus is a proteoglycan. Digestion of TGF-beta 1-receptor complexes with glycosaminoglycan (GAG)-specific degradative enzymes yield core proteins of 115-140 kDa. Cell monolayers that had been predigested with GAG-specific degradative enzymes were capable of binding high levels of TGF-beta 1, but the size of the binding components was shifted from the high molecular weight species to the lower molecular weight core proteins, indicating that GAG chains are not necessary for TGF-beta 1 binding to the cell. The presence of GAG chains on the receptor subunit indicates that it has the potential for interaction with the extracellular matrix.

Hl histones from mammalian testes. Hlt is associated with spermatogenesis in humans.

Hlt is a testis-specific Hl histone variant associated with meiosis and post-meiotic stages of male germ cell development. We have now made tentative identification of Hlt in humans by a variety of criteria including electrophoretic and extractive properties. While Hlt was readily identified in extracts from normal testes, it was not detectable in extracts from aspermatogenic testes or from placenta. Identification of Hlt in humans confirms the widespread association of this unusual Hl variant with spermatogenesis among mammals ranging from rodents to primates.

H1 histone subfractions of mammalian testes. 2. Organ specificity in mice and rabbits.

H1 histones were examined in testes and somatic organs from mice and rabbits. They were extracted from washed chromatin by aqueous 5% (w/v) trichloroacetic acid and analyzed by several electrophoretic systems as well as column chromatography employing Bio-Rex 70. In each species the testicular H1 population contains at least two components that are scarce or absent in the somatic organs examined. The unusual testicular species do not appear to be phosphorylated derivatives. The studies in this and the accompanying report [Seyedin, S.M., & Kistler, W.S. (1979) biochemistry 18 (preceding paper in this issue) confirm that marked changes from the isomatic type H1 population are associated with spermatogenesis in mice, rabbits, and rats. However, in terms of electrophoretic and chromatographic behavior, the pattern of change in species specific.

Isolation and characterization of rat testis H1t. An H1 histone variant associated with spermatogenesis.

Rat testis contains a unique H1 histone variant (H1t) not detected in a variety of other rat organs. H1t is extracted from chromatin by salt as expected for an H1 component (released by 0.6 M NaCl but not by 0.3 M); however, in contrast to other mammalian H1 species, H1t is not extracted in significant amounts by 5% (w/v) trichloroacetic acid. H1t is undetectable in testes from 3-or 15-day-old rats, but is evident in extracts from 21-day-old animals. Its initial appearance in the developing testis thus correlates with the progression of germinal cells to the meiotic stage of differentiation. H1t was isolated in homogeneous form by extraction of whole tissue with 0.75 M perchloric acid, fractional precipitation with trichloroacetic acid, and two cycles of chromatography over a cation exchange resin (Bio Rex 70). The amino acid composition of H1t differs significantly from that of somatic type H1 variants (for example, higher arginine and methionine content). Its identification as an H1 species is supported by analysis of the two fragments resulting from treatment of the protein with N-bromosuccinimide. H1t, as well as the six recognized somatic type H1 components of rat testis may be resolved by two-dimensional polyacrylamide gel electrophoresis run in the absence of denaturants at pH 4.5 in the first dimension and in the presence of sodium dodecyl sulfate in the second dimension.

H1 histones of trout.

H1 histones from trout testis, kidney, and liver were purified and characterized. They were extracted directly from tissues by aqueous 0.74 M perchloric acid and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis, as well as by ion exchange chromatography employing Bio-Rex 70. While in each case there was a single major H1 band on sodium dodecyl sulfate polyacrylamide gel electrophoresis, the elution patterns from Bio-Rex 70 appeared complex and indicated microheterogeneity. Moreover, by electrophoresis, as well as chromatography, extracts from kidney and liver were observed to contain additional component(s) not found in testis. These components were remarkable H1 subfractions in that they contained methionine and multiple tyrosine residues. Trout testis H1 is unusual in that it has been found to be essentially homogeneous in primary structure (Macleod, A. R., Wong, C. W., and Dixon, G. H. (1977) Eur. J. Biochem. 78, 281-291), while H1 from any other source that has been scrutinized rigorously has shown microheterogeneity. The present observation, that trout tissues generally have multiple H1 subfractions, established that the trout is not exceptional among organisms in possessing a single type of H1. Rather, it is the testis that is unusual among trout tissue in the homogeneity of its H1 population.

Loss of chromosomal high mobility group proteins HMG1 and HMG2 when mouse neuroblastoma and Friend erythroleukemia cells become committed to differentiation.

Chromosomal high mobility group (HMG) proteins HMG1 and HMG2 from mouse neuroblastoma cells and Friend erythroleukemic cells were analyzed by acetic acid/urea/polyacrylamide gel electrophoresis. Compared to rapidly growing cells, levels of HMG1 and HMG2 were decreased in mouse neuroblastoma cells that had been induced to differentiate by serum deprivation. This comparison revealed a reciprocal relationship between these HMG proteins and H10, a histone known to be in higher concentrations in nondividing cells. When cell growth was inhibited by means of density inhibition, however, HMG1 and -2 levels were not affected in either HeLa or mouse neuroblastoma cells, even though H10 did not accumulate. This observation establishes that HMG1 and -2 contents are not correlated with mitotic rate per se. Treatment of mouse neuroblastoma by sodium butyrate, which stops cell division without commitment to differentiation, had no effect on the level of HMG1 and -2. However, the level was decreased by dibutyryl cyclic AMP and dimethyl sulfoxide treatments, which, like serum deprivation, induced irreversible morphological differentiation in the neuroblastoma cells. Moreover, induction of differentiation (hemoglobin synthesis) in Friend erythroleukemic cells by dimethyl sulfoxide showed a decrease in the contents of HMG1 and -2. These observations suggest that preferential loss of HMG1 and -2 in mouse neuroblastoma and Friend erythroleukemia cells may be related to commitment of these cells to differentiation.

Chondrogenesis in agarose gel culture. A model for chondrogenic induction, proliferation and differentiation.

An in vitro model has been developed to study chondrogenic induction, proliferation and differentiation. Embryonic rat mesenchymal cells isolated from muscle and embedded in agarose were treated with a partially purified extract from bovine demineralized bone powder. Treated cells proliferated and synthesized matrix similar to differentiated chondrogenic cells in a dose-dependent manner. By employing an enzyme-linked immunosorbent assay (ELISA), cartilage-specific proteoglycan and type II collagen synthesis were quantitated. Of the cells tested, only embryonic mesenchymal cells from muscle responded to bone extract. Proteoglycan synthesis was sensitive to type of medium and cell density.